Anticoagulant Treatment
We recommend
Incidence of Osteoporosis in Patients with Atrial Fibrillation Treated with Different Oral Anticoagulants
Previous research has suggested an increased risk of osteoporosis and osteoporotic fractures in patients with atrial fibrillation treated with warfarin. A recent analysis also identified a higher incidence of osteoporosis in patients treated with warfarin or direct oral anticoagulants (DOACs). However, less is known about the risk of this disease when using DOACs compared to warfarin. Therefore, Australian doctors compared its incidence in patients treated with different oral anticoagulants for atrial fibrillation (AF) in a population…
Predictors and Rate of Anticoagulant Therapy Discontinuation in Patients with Atrial Fibrillation
With the worldwide increase in the prevalence of atrial fibrillation (AF), the use of…
Patient with a History of DOAC Usage in Neurological ICU with Stroke – Case Study
How should we approach patients with a stroke who are taking direct oral anticoagulants (DOACs) and…
Articles on this topic
Cardiovascular Interventions with Continued Therapy with Dabigatran − Insights from the GLORIA-AF Study
An analysis using data from an international registry of patients with newly diagnosed atrial…
Does adding statins to DOACs reduce the risk of major bleeding in patients with non-valvular atrial fibrillation?
A large retrospective study, the results of which were recently published, investigated to…
ESC 2022: What Current Insights Say About the Role of Dabigatran in Stroke Prevention with Atrial Fibrillation and Comorbidities
The risk of atrial fibrillation (AF) increases with age as risk factors accumulate and…
ESC 2022: What Do the Latest Real-World Data Say About the Use of DOACs in Atrial Fibrillation?
Why are real-world data so important? What new insights can they provide about established…
Risks Associated with Higher Residual Concentrations of Dabigatran in Seniors and Their Prevalence
Dabigatran is a direct thrombin inhibitor indicated for patients across the age spectrum. The…
Comparison of Dabigatran and Vitamin K Antagonists in Patients with Atrial Fibrillation in Real-World Practice
The final 3-year results of the GLORIA-AF study conducted in real-world practice with patients…
Luck in Unluckiness: Influence of Anticoagulant Therapy on Severity of Stroke in Atrial Fibrillation
A recent Swiss study evaluated the severity, complications, and outcomes of cerebrovascular…
Effectiveness of Idarucizumab Reversal Effect
It is, of course, a great advantage if doctors have a specific substance available that…
Use of Specific Inhibition of Anticoagulant Therapy During Heart Transplantation
A recent report from real clinical practice summarizes the experiences of physicians with…
Safety of Dabigatran in Secondary Prevention of Venous Thromboembolism in Pediatric Patients
Low molecular weight heparin (LMWH) or warfarin (VKA – vitamin K antagonist) is typically used…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Change in Release of Medication Pradaxa
- New Recommendations for Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke – ESO Guidelines 2021
- Effect of Initiation of Warfarin Therapy on the Risk of Ischemic Stroke
- Perioperative Management in Patients with Atrial Fibrillation Treated with NOACs
- Intravenous Thrombolysis in Ischemic Stroke Patients on Dabigatran Treatment
- How to Secure Diabetics with Atrial Fibrillation During PCI?
Journal on this topic
Related topic